Bladder cancer
Select a topic ( ) of interest
- Challenges in high-risk NMIBC
- NEW --- Adjuvant treatment approaches for MIBC
- UPDATED --- Histological subtypes of (N)MIBC: managed differently compared to pure UCa?
- UPDATED --- First-line therapy of synchronous and metachronous metastatic UCa
- Immunotherapy and antibody-drug conjugates: handling AEs and special populations
- New hope for patients progressing after prior treatment for mUCa
- Initial treatment of MIBC
- Follow-up surveillance regimes to consider for (very) high-risk NMIBC and MIBC
- Follow-up surveillance regimes for low-/intermediate-risk NMIBC
- Low- and intermediate-risk NMIBC: surveillance or intravesical therapy?